Population pharmacokinetics of busulfan in Saudi pediatric patients undergoing hematopoietic stem cell transplantation.

International Journal of Clinical Pharmacy
Abdullah AlsultanSalman Alfadhel

Abstract

Background Busulfan is an antineoplastic drug that is used widely as part of a conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation. It has a narrow therapeutic index and highly variable pharmacokinetics; therefore therapeutic drug monitoring is recommended to optimize busulfan dosing. Objective To study the population pharmacokinetics of busulfan in Saudi pediatric patients to optimize its dosing. Settings King Abdullah Specialist Children's Hospital in Riyadh, Saudi Arabia. Methods This pharmacokinetic observational study was conducted between January 2016 and December 2018. All pediatric patients receiving IV busulfan and undergoing routine therapeutic drug monitoring were included. Population pharmacokinetics modeling was conducted using Monolix2019R1. Pharmacokinetic data of busulfan in children. Results The study included 59 patients and 513 samples. The mean ± SD age was 6.10 ± 3.17 years, and the dose administered was 0.994 ± 0.15 mg/kg. The mean ± SD Cmax and area under the curve (AUC) were 900.60 ± 402.8 ng/mL and 1031.14 ± 300.75 µM min, respectively. Based on our simulations, the European Medicines Agency recommended dose were adequate for most patient's groups to achieve the...Continue Reading

References

Jan 1, 1991·Cancer Chemotherapy and Pharmacology·M HassanI Wallin
Jan 1, 1989·European Journal of Clinical Pharmacology·M HassanB Simonsson
Jan 10, 2002·Bone Marrow Transplantation·A M BolingerM J Cowan
Feb 9, 2002·Pediatric Hematology and Oncology·N KrivoyJ M Rowe
Dec 29, 2006·Journal of Clinical Pharmacology·Brian P BoothJogarao V S Gobburu
Jan 11, 2007·Journal of Pharmacokinetics and Pharmacodynamics·Marc Lavielle, France Mentré
Jan 27, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Imke H BartelinkJaap Jan Boelens
Jun 30, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G J VealG Vassal
Sep 14, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Radojka M SavicJanel Long-Boyle
Sep 26, 2013·Therapeutic Drug Monitoring·Marc AnsariUNKNOWN Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group
Nov 13, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeannine S McCuneNicholas H G Holford
May 9, 2014·European Journal of Clinical Pharmacology·Christian DiestelhorstGeorg Hempel
Mar 31, 2015·British Journal of Clinical Pharmacology·Francine A de CastroO Della Pasqua
Aug 3, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jeanne PalmerPaul A Carpenter
Aug 3, 2017·Expert Opinion on Drug Metabolism & Toxicology·Alan L MyersBorje S Andersson
Aug 16, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Tiago NavaHenrique Bittencourt
Oct 28, 2017·Journal of Clinical Pharmacology·Yasuyoshi IshiwataMasato Yasuhara
Apr 18, 2018·Journal of Clinical Pharmacology·Atsuko KawazoeSeongryul Kim
May 29, 2019·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jeannine S McCuneL Lee Dupuis

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Expert Opinion on Drug Metabolism & Toxicology
Jeannine S McCune, Leona A Holmberg
Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses
A S O'Marcaigh, D L Betcher
© 2021 Meta ULC. All rights reserved